Zentalis Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Updates
Zentalis Pharmaceuticals, Inc. (ZNTL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Zentalis Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Updates • DENALI Part 1b survival data strengthen azenosertib's position as the potential first-in-class oral, non-chemotherapy, non-ADC therapy in pivotal development for Cyclin E1-po
How this was made
The 30-second read
Why it matters
For trading, the most decision-relevant items are the newly disclosed DENALI Part 1b overall survival results by Cyclin E1 status, the scheduled completion of DENALI Part 2c enrollment in November 2026, and the expected integrated topline readout in 1H 2027, supported by an updated cash runway into 1H 2028.
Market read
This filing provides a near-term catalyst map (DENALI Part 2c completion in November 2026, integrated topline in 1H 2027) and supportive efficacy signals (DENALI Part 1b OS, ORR, DOR) that can re-rate risk for azenosertib’s regulatory and valuation trajectory.
What to watch
The filing also notes an evolving PROC landscape and plans to discuss accelerated approval in 2027, which can introduce uncertainty around FDA feedback timing and the probability-weighting of the accelerated pathway.
Zentalis reports Q3 2026 net loss of $(28,815) thousand and $228.9 million in cash, runway into 1H 2028; DENALI Part 2 topline expected 1H 2027
Operating expenses fell year over year and the company reports $228.9 million in cash with runway into 1H 2028, but the period is a net loss, the filing has no revenue, and the FDA discussion on accelerated approval is now planned for 2027 with the DENALI topline in 1H 2027.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Research and development expenses, Q3 2026 (three months ended Sep 30, 2026)GAAP | $22.3M | – | $0.7 million decrease |
| General and administrative expenses, Q3 2026GAAP | $8.8M | – | $2.0 million decrease |
| Total operating expenses, Q3 2026GAAP | $31.2M | – | – |
| Loss from operations, Q3 2026GAAP | −$31.15M | – | – |
| Investment and other income, net, Q3 2026GAAP | $2.46M | – | – |
| Net loss before income taxes, Q3 2026GAAP | −$28.70M | – | – |
| Income tax expense, Q3 2026GAAP | $118K | – | – |
| Net loss, Q3 2026GAAP | −$28.82M | – | – |
| Net loss per common share, basic and diluted, Q3 2026GAAP | $(0.34) | – | – |
| Research and development expenses, nine months ended Sep 30, 2026GAAP | $86.21M | – | – |
| General and administrative expenses, nine months ended Sep 30, 2026GAAP | $27.19M | – | – |
| Restructuring expenses, nine months ended Sep 30, 2026GAAP | no amount printed (dash shown) | – | – |
| Total operating expenses, nine months ended Sep 30, 2026GAAP | $113.4M | – | – |
| Loss from operations, nine months ended Sep 30, 2026GAAP | −$113.4M | – | – |
| Investment and other income, net, nine months ended Sep 30, 2026GAAP | $7.32M | – | – |
| Net loss before income taxes, nine months ended Sep 30, 2026GAAP | −$106.1M | – | – |
| Income tax expense, nine months ended Sep 30, 2026GAAP | $376K | – | – |
| Net loss, nine months ended Sep 30, 2026GAAP | −$106.5M | – | – |
| Net loss per common share, basic and diluted, nine months ended Sep 30, 2026GAAP | $(1.41) | – | – |
| Cash, cash equivalents and marketable securities, as of Sep 30, 2026other | $228.9M | – | – |
| Working capital, as of Sep 30, 2026 (company definition: current assets less current liabilities)other | $204.9M | – | – |
| Total assets, as of Sep 30, 2026GAAP | $270.2M | – | – |
| Total liabilities, as of Sep 30, 2026GAAP | $65.31M | – | – |
| Total Zentalis equity, as of Sep 30, 2026GAAP | $204.9M | – | – |
Capital returns
- No share repurchases or dividends are reported in the filing.
- Follow-on equity offering completed in August 2026: 26,450,000 shares of common stock, with approximately $86.9 in net proceeds (the filing does not print a unit for this figure).
What drove it
- Research and development decrease of $0.7 million: the company attributes it primarily to a $6.2 million decrease in clinical trial expenses for certain studies that reached or are near completion, partially offset by a $3.8 million increase in expenses for ongoing clinical trials open for enrollment, a $0.8 million increase in companion diagnostic development expenses and a $0.9 million increase in personnel-related expenses and allocated overhead.
- General and administrative decrease of $2.0 million: the company attributes it primarily to a $2.7 million decrease in personnel-related expenses, partially offset by a $0.7 million increase primarily related to consulting and outside services.
- Cash increase from $174.6 million to $228.9 million quarter over quarter: the company states this includes net proceeds from the August 2026 follow-on offering.
- Clinical data: the company presented DENALI Part 1b overall survival data at ESMO in October 2026. In Cyclin E1-positive PROC patients (n=48), median OS was 15.9 months (95% CI, 8.7-21.2), versus 7.5 months (95% CI, 5.8-12.3) in Cyclin E1-negative patients (n=46). Updated ORR in response-evaluable Cyclin E1-positive patients was 37.2%.
Concerns
- The company has no revenue line in the filing and reports a net loss of $(28,815) thousand for the quarter and $(106,453) thousand for the nine months.
- Investment and other income, net fell to $2,457 thousand in Q3 2026 from $7,043 thousand in Q3 2025, and to $7,323 thousand for nine months from $13,571 thousand. The filing does not explain this change.
- The company plans to discuss the DENALI data with the FDA in 2027 to assess the accelerated approval opportunity, citing an evolving landscape in PROC.
- Stated cash runway runs into the first half of 2028, which is about one year beyond the DENALI topline readout expected in the first half of 2027, and the company notes the offering that supported the balance.
- Azenosertib has not been approved by the U.S. FDA or any other regulatory authority, as stated in the filing.
What to watch
- DENALI Part 2c enrollment completion, scheduled for November 2026.
- DENALI Part 2 integrated topline readout across Parts 2a, 2b and 2c, expected in the first half of 2027.
- Timing and outcome of the planned 2027 FDA discussion on accelerated approval.
- ASPENOVA Phase 3 site initiations and enrollment, expected to enroll approximately 420 patients, with PFS as the primary endpoint.
- MUIR Phase 1b enrollment (azenosertib with bevacizumab in platinum-sensitive ovarian cancer) and the planned triple-negative breast cancer combination study.
- Cash and operating expense trends against the stated runway into the first half of 2028.
Balance sheet and cash flow
- Cash, cash equivalents and marketable securities were $228.9 million as of Sep 30, 2026, compared with $174.6 million as of June 30, 2026, including net proceeds from the August 2026 follow-on offering.
- Balance sheet data as of Dec 31, 2025 printed in the filing: cash, cash equivalents and marketable securities $245,893 thousand; working capital $216,632 thousand; total assets $288,967 thousand; total liabilities $72,763 thousand; total Zentalis equity $216,204 thousand.
- Company states that existing cash, cash equivalents and marketable securities will be sufficient to fund operating expenses and capital expenditure requirements into the first half of 2028.
- No operating, investing or financing cash flow figures are printed in the filing.
Analysis
Zentalis reported a third quarter 2026 net loss of $(28,815) thousand, or $(0.34) per share, compared with a net loss of $(26,691) thousand, or $(0.37) per share, in the third quarter of 2025. The filing contains no revenue line. Total operating expenses fell to $31.2 million from $33.7 million, with research and development down $0.7 million to $22.3 million and general and administrative expenses down $2.0 million to $8.8 million. The company attributes the R&D decline mainly to lower clinical trial expenses for studies that reached or are near completion, partly offset by spending on trials open for enrollment and companion diagnostic development. Investment and other income, net was $2,457 thousand, down from $7,043 thousand a year earlier, and the filing does not give a reason for that change.
On the nine-month view, operating expenses were $113,400 thousand against $115,415 thousand, with R&D up to $86,213 thousand from $77,807 thousand and a $7,796 thousand restructuring charge in the 2025 period that does not recur in the 2026 period. Net loss for the nine months was $(106,453) thousand, or $(1.41) per share, against $(101,844) thousand, or $(1.42) per share. Income tax expense was $118 thousand for the quarter and $376 thousand for the nine months, with no comparable tax line printed for the prior-year quarter.
The balance sheet strengthened in the quarter. Cash, cash equivalents and marketable securities rose to $228.9 million from $174.6 million at June 30, 2026, and the company attributes the increase in part to the August 2026 follow-on offering of 26,450,000 shares, with approximately $86.9 in net proceeds (the filing prints no unit for that figure). Compared with December 31, 2025, cash of $245,893 thousand fell to $228,893 thousand, and total assets declined from $288,967 thousand to $270,193 thousand. Total Zentalis equity was $204,887 thousand. The company states that current resources will fund operating expenses and capital expenditure requirements into the first half of 2028.
Clinically, the central development points are the DENALI Part 1b overall survival data presented at ESMO, with median OS of 15.9 months in Cyclin E1-positive patients versus 7.5 months in Cyclin E1-negative patients, and an updated ORR of 37.2% in response-evaluable Cyclin E1-positive patients. DENALI Part 2c enrollment is scheduled to complete in November 2026, with an integrated Part 2 topline readout expected in the first half of 2027. The company also stated it will discuss the DENALI data with the FDA in 2027 to assess accelerated approval, which places the regulatory discussion after the topline readout window opens. The filing gives no financial guidance for 2026 or 2027.
Management, verbatim
Overall survival data from DENALI Part 1b presented at ESMO reinforce our confidence in azenosertib to offer a differentiated oral treatment for patients with Cyclin E1-positive platinum-resistant ovarian cancer (PROC), if approved,
Julie Eastland, Chief Executive Officer, Zentalis Pharmaceuticals
In light of an evolving landscape in PROC, we plan to discuss the DENALI data with the FDA in 2027 to assess the accelerated approval opportunity.
Julie Eastland, Chief Executive Officer, Zentalis Pharmaceuticals
With $228.9 million on the balance sheet providing an anticipated runway into the first half of 2028, we believe we are well resourced to support key DENALI milestones, full enrollment in ASPENOVA and combination trials in ovarian cancer and triple-negative breast cancer,
Julie Eastland, Chief Executive Officer, Zentalis Pharmaceuticals
Not in the filing
stated, not guessed- Revenue or license income for any period: the filing has no revenue line.
- Prior-year and prior-quarter comparisons for total operating expenses, loss from operations, investment income, pre-tax loss, net loss and EPS in the three-month table: the filing prints the change for R&D and G&A only.
- Year-over-year changes for the nine-month lines: not printed.
- Prior-year comparison for income tax expense: the prior-period figure is shown as a dash with no amount.
- Prior-quarter comparison for the quarterly P&L lines: the filing does not print Q2 2026 operating results.
- Cash flow statement figures (operating, investing and financing cash flow) and free cash flow: not in the filing.
- Unit for the approximately $86.9 net proceeds from the August 2026 follow-on offering: not printed.
- Prior-year comparison for cash, total assets, total liabilities and total equity: the filing compares them with December 31, 2025, not with September 30, 2025.
- Financial guidance or outlook for 2026 or later: none provided in the filing.
- Prior-period outlook for vs_prior_guidance: not provided with this filing.
- Segment or product-line revenue breakdown: not provided.
- Gross margin, non-GAAP measures and adjusted EBITDA: not reported.
- Share price reaction and analyst consensus estimates: not in the documents.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
The 8-K (Item 2.02 and 7.01) furnishes Zentalis’ Q3 2026 financials and business updates for its WEE1 inhibitor azenosertib, including DENALI and ASPENOVA program milestones and conference disclosures.
Ticker impact
Zentalis reports Q3 2026 results and updates on DENALI Part 1b OS, DENALI Part 2c enrollment timing, and a planned FDA discussion for accelerated approval.
Likely upward bias as traders price in stronger DENALI efficacy signals and a clearer path to a 1H 2027 topline and potential FDA accelerated-approval discussion.
The filing includes specific OS/ORR/DOR figures for Cyclin E1-positive PROC, a scheduled DENALI Part 2c completion in November 2026, and an expected integrated topline readout in 1H 2027, plus $228.9M cash runway into 1H 2028.
Market effects
Adds incremental sentiment support for late-stage oncology biotech WEE1 inhibition and biomarker-driven ovarian cancer programs, but is single-company specific.
Primarily impacts US small/mid-cap biotech sentiment; limited spillover beyond Nasdaq biotech complex.
ESMO-presented data may influence international biotech investor positioning, but the trading catalyst is company-specific and US-listed.
Counterpoint
OS benefit is presented for a relatively small biomarker subgroup (n=48 Cyclin E1-positive), so traders may discount durability and regulatory translation until FDA engagement details or larger datasets emerge.
Key entities
- companyZentalis Pharmaceuticals, Inc.
Nasdaq-listed clinical oncology company advancing azenosertib (WEE1 inhibitor) in ovarian cancer and other tumor types.
- productAzenosertib
Investigational, orally bioavailable WEE1 inhibitor being evaluated in DENALI/ASPENOVA and combination studies.
- clinical_programDENALI
Azenosertib pivotal development program in Cyclin E1-positive platinum-resistant ovarian cancer, with Part 1b OS data and Part 2c enrollment timing.
- clinical_programASPENOVA
Phase 3 study evaluating azenosertib in Cyclin E1-positive PROC, with enrollment ongoing.
- clinical_programMUIR
Azenosertib combination study with bevacizumab in platinum-sensitive ovarian cancer, enrolling as maintenance treatment.
